EZINWANYI MARK: Open Payments
NPI 1780374900 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,008 in 37 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $1,008
Food & beverage: $1,008
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $169 |
| Janssen Pharmaceuticals, Inc | 5 | $169 |
| Teva Pharmaceuticals USA, Inc. | 7 | $149 |
| Alkermes, Inc. | 2 | $148 |
| Vanda Pharmaceuticals Inc. | 1 | $115 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $104 |
| ABBVIE INC. | 3 | $64 |
| Neurocrine BioSciences, Inc. | 2 | $54 |
| Lundbeck LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
Products named: INVEGA SUSTENNA, AUSTEDO XR, REXULTI, LYBALVI, FANAPT, CAPLYTA, VRAYLAR, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
